Christopher Guenard
Experienced biotech BD leader and former strategy consultant. Select transactions include: 3.2B acquisition of Translate Bio by Sanofi... | Greater Boston, Greater Boston, United States
*50 free lookup(s) per month.
No credit card required.
Christopher Guenard’s Emails cg****@ph****.com
Christopher Guenard’s Phone Numbers No phone number available.
Social Media
Christopher Guenard’s Location Greater Boston, Greater Boston, United States
Christopher Guenard’s Expertise Experienced biotech BD leader and former strategy consultant. Select transactions include: 3.2B acquisition of Translate Bio by Sanofi Pasteur (2022) 425M upfront / 2.3B total deal value licensing agreement between Translate Bio and Sanofi Pasteur (2021) Out-license of maralixibat and volixibat from Shire to Mirum Pharmaceuticals for 14.5M upfront (cash and stock) (2018) 5.9B acquisition of Dyax by Shire (2016)
Christopher Guenard’s Current Industry Photys Therapeutics
Christopher
Guenard’s Prior Industry
Massachusetts General Hospital
|
Hospital Ramon Y Cajal
|
Clearview Healthcare Partners
|
Cubist Pharmaceuticals
|
Shire Pharmaceuticals
|
Translate Bio
|
Sanofi
|
Photys Therapeutics
Not the Christopher Guenard you were looking for?
Find accurate emails & phone numbers for over 700M professionals.
Work Experience
Photys Therapeutics
Vice President Corporate Development
Sat Oct 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) — Present
Sanofi
Integration Lead
Wed Sep 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) — Sat Oct 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Translate Bio
Senior Director, Corporate Development and Strategy
Mon Mar 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) — Wed Sep 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Translate Bio
Director Of Business Development
Sun Sep 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) — Mon Mar 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Translate Bio
Associate Director of Business Development
Sun Jul 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Sep 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Shire Pharmaceuticals
Associate Director of Scientific Licensing
Sun Mar 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Jun 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Cubist Pharmaceuticals
Business Development Analyst
Mon Dec 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Feb 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Clearview Healthcare Partners
Analyst
Sun Jul 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time) — Sat Nov 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Massachusetts General Hospital
Researcher
Tue Feb 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Jan 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Hospital Ramon Y Cajal
Intern in Department of Neurology
Sat May 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time) — Thu Jul 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Massachusetts General Hospital
Researcher
Fri May 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) — Sat Jan 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)Skills
Languages
Christopher Guenard Email Addresses
FAQ About Christopher Guenard
-
Christopher Guenard is located at
Greater Boston, Greater Boston, United States -
Christopher Guenard is a
Experienced biotech BD leader and former strategy consultant. Select transactions include: 3.2B acquisition of Translate Bio by Sanofi Pasteur (2022) 425M upfront / 2.3B total deal value licensing agreement between Translate Bio and Sanofi Pasteur (2021) Out-license of maralixibat and volixibat from Shire to Mirum Pharmaceuticals for 14.5M upfront (cash and stock) (2018) 5.9B acquisition of Dyax by Shire (2016) Photys Therapeutics -
Christopher Guenard currently works in the
Photys Therapeutics -
Christopher Guenard specializes in
Experienced biotech BD leader and former strategy consultant. Select transactions include: 3.2B acquisition of Translate Bio by Sanofi Pasteur (2022) 425M upfront / 2.3B total deal value licensing agreement between Translate Bio and Sanofi Pasteur (2021) Out-license of maralixibat and volixibat from Shire to Mirum Pharmaceuticals for 14.5M upfront (cash and stock) (2018) 5.9B acquisition of Dyax by Shire (2016) -
Christopher Guenard speaks the following languages:
No languages available. -
Christopher Guenard has prior experience in the following industries:
Sanofi , Translate Bio , Translate Bio , Translate Bio , Shire Pharmaceuticals , Cubist Pharmaceuticals , Clearview Healthcare Partners , Massachusetts General Hospital , Hospital Ramon Y Cajal , Massachusetts General Hospital -
Christopher Guenard has the following professional experience:
Photys Therapeutics , Sanofi , Translate Bio , Translate Bio , Translate Bio , Shire Pharmaceuticals , Cubist Pharmaceuticals , Clearview Healthcare Partners , Massachusetts General Hospital , Hospital Ramon Y Cajal , Massachusetts General Hospital . -
You can view Christopher Guenard’s
LinkedIn profile at LinkedIn URL. -
Christopher Guenard’s work email addresses are
[email protected] . -
Christopher Guenard works at
Photys Therapeutics
People you may be interested in
- Edward Glace
- Kirsty Dakin
- Joanna Roberts
- Omoviekovwa Nakireru
- Peter Arrowsmith
- Shari Peterson
- Corey Campbell
Project Engineer at Messer Construction
Supply Chain Study Manager at AstraZeneca
Enablement professional with a specialty in program management and 17+ years experience in SaaS. I love helping others succeed and grow in their careers, and am skilled at building programs, processes & partnerships.
Chaplain at Palmetto Health
Technical Consultant
Principal
Portfolio Manager at Caterpillar • I Define, Develop & Deliver Enterprise-Wide Initiatives, New Products & Strategies